Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03000283 · ClinicalTrials.gov registry record · Phase 1

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

A Phase 1 study of Stroke and Intracerebral Hemorrhage, sponsored by Jesse Corry.

Completed
Registry status
Phase 1
Development phase
7
Enrollment target
1
Study location

NCT03000283: Completed Phase 1 study of Stroke and Intracerebral Hemorrhage, sponsored by Jesse Corry.

NCT03000283 is a Phase 1 study of Stroke and Intracerebral Hemorrhage that has completed, run by Jesse Corry. The registered enrollment target is 7 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03000283, a Phase 1 study of Stroke and Intracerebral Hemorrhage, has completed, sponsored by Jesse Corry.

COMPLETED
Registry status
Phase 1
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A further goal is to preliminarily estimate whether conivaptan at this same dose can reduce cerebral edema (CE) in these same patients. This study is also an essential first step in understanding the role of conivaptan in CE management. Hypothesis: The frequent and early use of conivaptan at 40mg/day will be safe and well-tolerated, and also reduce cerebral edema, in patients with intracerebral hemorrhage and pressure.

Primary Outcome

The number of participants with abnormal seizure activity and/or abnormal lab values and/or increase in infection rate and/or any drug-related adverse events.

Conditions Studied

Stroke Intracerebral Hemorrhage Cerebral Edema Cerebral Hemorrhage

Interventions

  • DRUG Conivaptan

Study Locations (1)

Minnesota

  • United Hospital - Saint Paul

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2017-03-22
Est. Completion 2019-04-15
Phase Phase 1
Jesse Corry

1 total trials

What the finished NCT03000283 record still lists

NCT03000283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).

The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Conivaptan is the first listed.

NCT03000283 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT03000283 about?

NCT03000283 is a clinical study titled "Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study". The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A fu...

What is the current status of trial NCT03000283?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-03-22. Estimated completion is 2019-04-15.

What conditions does trial NCT03000283 study?

This clinical trial studies the following conditions: Stroke, Intracerebral Hemorrhage, Cerebral Edema, Cerebral Hemorrhage.

What interventions are being tested in trial NCT03000283?

The interventions under investigation include: Conivaptan (DRUG).

Who is sponsoring clinical trial NCT03000283?

This trial is sponsored by Jesse Corry, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03000283 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03000283's enrollment target sits among peer trials

7 430th of 454 higher than 23 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03000283, the US trial registry maintained by the National Library of Medicine. NCT03000283 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.